Next Phase Newsletter

A venture fund formed by a group of high net-worth individuals in China has team members and portfolio companies located in Shanghai, Nanjing, Silicon Valley, and New York. The fund is currently seeking investment opportunities globally with a focus on China and the US. Projects based in Canada and the DACH region may also be considered.

The fund pays close attention to investment opportunities from seed and early stages to growth stage. For seed and early stage projects, the fund makes investments in convertible notes and equity and is flexible on investment size. For growth stage projects, the fund makes equity investments of US$1-5 million in businesses with valuation of up to US$18-20 million. Due to its evergreen fund structure, the fund takes a long-term approach to investment. The fund typically syndicates in a financing round and would like to partner with local co-investors in case of overseas investments.

The fund focuses on high-growth fields in biotech therapeutics, medical devices, digital health, and consumer products with an elevated interest in diagnostics. The firm is agnostic to disease areas. In diagnostics, the fund is interested in portable imaging devices, high-intensity ultrasound, point-of-care diagnostics, and molecular diagnostics. In digital health, the fund is interested in technologies that can be applicable to the Chinese market, such as connected devices, telemedicine, and patient-physician platforms. In consumer products, the fund in interested in OTC, nutrition and dietary supplements that have proven efficacy and are on market.

The fund is looking to work with serial entrepreneurs from seed and early stages to growth stage to form complete and strong teams. The fund typically cooperates with local co-investors who play a supervisory role in overseas operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private specialty pharmaceutical company with offices all around the world has a venture fund that focuses on early stage companies.  The firm positions itself to be a strategic corporate partner to develop and support innovative technologies in the aesthetics and cosmetics space. The firm typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.

The firm focuses only on aesthetics with an anti-aging focus, including skin rejuvenation, body shaping and modification. The firm is open to all therapeutics, medical devices, and healthcare IT, as long as the technology serves an unmet need/gap in the aesthetic marketplace. The firm historically invested in injectables, toxins, topicals, cosmetics, and devices. The firm typically looks at seed to early stage companies, and specifically focuses on pre-clinical to clinical stage technology with substantial data.

As a strategic corporate partner, the firm hopes to bring its own expertise and internal resources to the table. As not only an investor, but also as a strategic partner, the firm anticipates being able to offer advice, support, and consultation for the early-stage company to leverage its global comprehensive network of experts within the firm, and can offer R&D, clinical, regulatory through to commercial, sales and marketing expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm based in New York, NY has launched a health technology fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The fund focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; or provide more meaningful tracking of health metrics for patients (health and wellness analytics).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Hong Kong makes seed and early stage investments across several sectors including the life sciences. The firm typically allocates USD 75K to 500K per company as well as possible continuation into Series A. The firm can invest globally and is actively seeking new investment opportunities.

In the life sciences, the firm is interested in DNA genetic testing. For example, technologies such as pre-natal testing and DNA testing for oncology screening. The firm is also interested in and health & wellness technology for preventive care or management of chronic illness such as diabetes. The firm will focus on startups that have already gained some traction. The firm historically invested in molecular diagnostics and DNA screening.

The firm looks to partner with exceptional entrepreneurs and generally looks to take a board seat post investment, though this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the United Kingdom seeks to invest in companies that need capital within the range of £1m to £10m with a typical investment size at £3 million per company. The firm focuses on investments in life science companies at clinical or growth stage. The firm has a syndicated fund of £100 million, and seeks to make 1-2 new investments within the next year in addition to their current portfolio of 8 active companies. The firm typically leads investments, though will co-invest depending on the opportunity. The firm focuses on UK-based private companies, though is open to companies based in Europe and the U.S.

The firm is currently looking for new opportunities in the Medical Technology and Therapeutics sectors. The firm will also consider diagnostics companies, depending on the opportunity. For therapeutics, the firm will invest in both small molecules and biologics. The firm will consider all classes of medical devices, and prefers to invest in devices with a regulatory pathway. The firm invests in clinical-stage to commercialized products, and prefers clinical-stage technology with a clear path towards revenue.

The firm focuses on private companies and prefers companies with a strong management team and significant growth potential that are able to deliver returns for investors within a 3 to 5-year timetable. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the central US is currently in the process of raising its 2nd fund, targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm typically makes 6-8 allocations per year, and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in telemedicine, healthcare IT, pathology, diagnostics, bioinformatics, medical devices, and healthcare automation. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to work with them. The firm looks to take a board seat following investment. In addition to capital, the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices in the USA and Europe manages focused private equity funds for family offices and high-net worth individuals. The firm seeks to transform SMEs with local traction to global front-runners. Their typical investment size is $1 M – 20 M. They are looking to make 4 new investments in the next year, and are currently focused on OTM medical technology.

The firm is opportunistic and will consider deals across the life sciences board, but is currently focused on medical technology, industrial processes, materials, HCIT and digital health with high tech underpinnings, and food production, distribution, and transformation.

The firm desires an experienced, passionate team of entrepreneurs with international experience, capable of building a fast growing global business. They do not invest in start ups. They look to acquire 20-80% equity in SME’s with $3-5 M in revenue, or fast growing companies that will be generating revenue within a year with all regulatory barriers cleared. They require a clear, scalable path to globalization. The firm pursues a 60-day due diligence period when considering a deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com